AAVXF OTC

Abivax S.A., a French biopharmaceutical firm, specializes in the discovery and enhancement of pharmaceutical treatments targeting inflammatory conditions, infectious illnesses, and various forms of cancer. The company's flagship compound, ABX464, is currently undergoing Phase IIb clinical evaluations for ulcerative colitis, Crohn's disease, and COVID-19. It is also being assessed in Phase IIa trials for rheumatoid arthritis, and has successfully concluded Phase IIa studies demonstrating viral remission in individuals with HIV. Additionally, Abivax is advancing ABX 196, an investigational immune-enhancing agent, through Phase 1/2 clinical trials for its potential application in treating hepatocellular carcinoma. Further research initiatives by the company explore therapies for Dengue fever, influenza, and respiratory syncytial virus. Abivax S.A. holds licensing agreements with prominent French research institutions, including the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Established in 2013, the company maintains its primary offices in Paris, France.